Legislative Updates, GLP-1s, and More at AMCP Nexus: Adam Colborn

At this year’s AMCP Nexus meeting, attendees will get to hear insights from stakeholders across the care continuum, said Adam Colborn, JD, director of Government Affairs, AMCP.

Colborn will be speaking at 2 sessions: "Federal Legislative and Regulatory Update" and "State Legislative and Regulatory Update." He also highlighted a session on glucagon-like peptide-1 (GLP-1) receptor agonists, which he thinks is not only timely but also could be important for the second round of drug negotiations under the Inflation Reduction Act (IRA).

AMCP Nexus is being held October 14-17 in Las Vegas, Nevada.

This transcript has been lightly edited.

Transcript

What are you looking forward to at this year’s AMCP Nexus meeting?

Well, I always look forward to connecting with our members. It's a great opportunity to meet with experts from the entire pharmacy care continuum. We get folks from the payer side, with health plans and PBMs [pharmacy benefits managers], and we get folks who are working in the pharmaceutical industry. So, we get a really good cross section of the entirety of the care continuum there. And I think that's useful for sharing insight and information.

Obviously, I always look forward to the federal legislative update and the state legislative update that we deliver. In particular, this year, I think the session that I'm most interested in is a session on GLP-1 agonists, and so that, I think, is really timely and is a really interesting subject, especially as we look toward some of the issues in 2025. AMCP’s journal, the Journal of Managed Care & Specialty Pharmacy published an article last month predicting the 10 most likely drugs for round 2 of the IRA negotiations, and Ozempic was right at the top of that that list. And so, I think this is a really good time to have that conversation. I'm looking forward to the insights that the panelists will bring on that front.